Lenny Moise

Lenny Moise, PhD is Director of Vaccine Research at EpiVax, Inc. and Research Professor at the Center for Vaccines and Immunology at the University of Georgia. Dr. Moise received his PhD in Biology from the Department of Molecular and Cellular Biology and Biochemistry at Brown University in Providence, RI in 2002. His graduate research in Dr. Edward Hawrot’s laboratory focused on structure-function relationships of snake neurotoxin interactions with the nicotinic acetylcholine receptor. Dr. Moise’s postdoctoral training at Brown University involved functional analysis of toxin binding sites engineered into toxin-insensitive ion channels. In 2005, he joined Dr. Anne De Groot’s laboratory at Brown University as an Instructor in Medicine in the Department of Medicine (Infectious Disease) to study T cell-directed vaccines and protein therapeutic immunogenicity. Dr. Moise joined EpiVax, Inc. in Providence, RI in 2006 where he is currently Director of Vaccine Research. He leads T cell epitope-driven vaccine development projects using a genomes-to-vaccine approach that combines cutting edge immunoinformatic and experimental methods. He has applied this approach to several pathogen targets using epitope-based and whole antigen vaccine designs. His research also includes de-immunization of protein therapeutics by epitope modification. In 2008, Dr. Moise accepted a part-time appointment as Assistant Research Professor in the Department of Cell and Molecular Biology at the University of Rhode Island and was promoted to Associate Research Professor in 2014. He was a founding faculty member of the URI Institute for Immunology and Informatics, where he led vaccine and immunotherapeutic development projects. In 2020, Dr. Moise accepted a part-time appointment at the Center for Vaccines and Immunology at the University of Georgia. Dr. Moise has published over 90 original research manuscripts, chapters, opinions, reviews, and conference proceedings on vaccines and infectious diseases. He has been an ad hoc reviewer for NIH study sections and several journals and has received funding from the NIH, CDC, the American Thyroid Association and the Rhode Island Foundation.